Stay updated on ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page.

Latest updates to the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page
- Check2 days agoChange DetectedRevision tag updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedAdded Revision: v3.5.0. Removed Revision: v3.4.3.SummaryDifference0.1%

- Check38 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3. No study data, eligibility criteria, or location information appears to be affected.SummaryDifference0.1%

- Check67 days agoChange DetectedDifference0.4%

- Check74 days agoChange DetectedA government funding lapse notice about site status has been added, and the page version was updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check81 days agoChange DetectedMinor metadata and UI label updates were applied, including changes to update date labels (Last Update Submitted that Met QC Criteria and Last Update Posted), No FEAR Act labeling, a new Revision: v3.4.0, and the addition of a 'Show glossary' option. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page.